TG Therapeutics (NASDAQ:TGTX)‘s stock had its “buy” rating reaffirmed by equities research analysts at B. Riley in a research note issued on Monday. They presently have a $21.50 price target on the biopharmaceutical company’s stock. B. Riley’s price objective would suggest a potential upside of 152.94% from the company’s current price.

Several other research firms also recently commented on TGTX. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. HC Wainwright restated a “buy” rating and set a $33.00 target price (up previously from $18.00) on shares of TG Therapeutics in a research report on Tuesday, November 14th. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 24th. Finally, SunTrust Banks restated a “buy” rating and set a $28.00 target price on shares of TG Therapeutics in a research report on Tuesday, October 3rd. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the stock. TG Therapeutics currently has a consensus rating of “Buy” and an average price target of $25.50.

TG Therapeutics (NASDAQ TGTX) traded up $0.25 during trading on Monday, hitting $8.50. The company had a trading volume of 1,291,800 shares, compared to its average volume of 1,543,830. TG Therapeutics has a 1-year low of $4.10 and a 1-year high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last posted its earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). The company had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. TG Therapeutics had a negative return on equity of 151.21% and a negative net margin of 73,217.77%. analysts forecast that TG Therapeutics will post -1.86 earnings per share for the current fiscal year.

A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc increased its holdings in TG Therapeutics by 4.1% during the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 384 shares in the last quarter. Bank of America Corp DE increased its holdings in TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock valued at $164,000 after purchasing an additional 1,395 shares in the last quarter. California State Teachers Retirement System increased its holdings in TG Therapeutics by 1.9% during the 2nd quarter. California State Teachers Retirement System now owns 85,935 shares of the biopharmaceutical company’s stock valued at $864,000 after purchasing an additional 1,600 shares in the last quarter. Teachers Advisors LLC increased its holdings in TG Therapeutics by 7.1% during the 1st quarter. Teachers Advisors LLC now owns 75,432 shares of the biopharmaceutical company’s stock valued at $879,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Nationwide Fund Advisors increased its holdings in TG Therapeutics by 24.2% during the 2nd quarter. Nationwide Fund Advisors now owns 26,531 shares of the biopharmaceutical company’s stock valued at $267,000 after purchasing an additional 5,167 shares in the last quarter. 50.45% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “TG Therapeutics’ (TGTX) Buy Rating Reiterated at B. Riley” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.watchlistnews.com/tg-therapeutics-tgtx-buy-rating-reiterated-at-b-riley/1757758.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.